Clinical Lymphoma Myeloma and Leukemia 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Prognostic role of CDKN2A deletion and p53 expression and association with MIPIb in Mantle Cell Lymphoma
In this study, we investigated the prognostic role of MIPIb and the association with biological markers including SOX11, p53 expression, Ki-67 and CDKN2A.This retrospective study was focused on 23 patients with newly diagnosed classical MCL, treated at the University Hospital of Bari (Italy) between January 2006 and June 2019.We identified a MIPIb value ≥ 5.4440 as a prognostic parameter that correlates with p53 expression and CDKN2A deletion. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 19, 2023 Category: Hematology Authors: Francesco Gaudio, Michele Dicataldo, Fabrizia Di Giovanni, Gerardo Cazzato, Antonio d'Amati, Tommasina Perrone, Pierluigi Masciopinto, Filomena Emanuela Laddaga, Pellegrino Musto, Eugenio Maiorano, Giuseppe Ingravallo Tags: Original Study Source Type: research
SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on target
While the peripheral T-cell lymphomas (PTCL) remain a therapeutic challenge, and increasingly account for a disproportionate number of lymphoma-related deaths, improved understanding of disease pathogenesis and classification, and the development of novel therapeutic agents over the past decade, all provide reasons for a more optimistic outlook in the next. Despite their genetic and molecular heterogeneity, many PTCL are dependent upon signaling input provided by antigen, costimulatory, and cytokine receptors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 19, 2023 Category: Hematology Authors: Shannon A. Carty, Carlos A. Murga-Zamalloa, Ryan A. Wilcox Source Type: research
Hepatitis B virus reactivation in patients receiving Bruton tyrosine kinase inhibitors
: Bruton tyrosine kinase (BTK) inhibitors are used to treat B-cell hematologic malignancies. Ibrutinib has been associated with hepatitis B virus (HBV) reactivation. We sought to identify patients with hematologic malignancies who developed HBV reactivation after receiving first-generation (ibrutinib) or second-generation (acalabrutinib and zanubrutinib) BTK inhibitors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 19, 2023 Category: Hematology Authors: Chia-Yu Chiu, Sairah Ahmed, Sheeba K. Thomas, Lan Sun Wang, Khalis Mustafayev, Luis E. Fayad, William G. Wierda, Fareed Khawaja, Harrys A. Torres Tags: Original Study Source Type: research
Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 18, 2023 Category: Hematology Source Type: research
Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 18, 2023 Category: Hematology Source Type: research
Clinical outcomes in patients with covid-19 and hematologic disease
Since the beginning of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection outbreak, more vulnerable patient populations with various concomitant acute and chronic diseases have drawn particular attention from the medical and scientific community due to the numerous concerns regarding the complications, consequences, and outcomes of both the coronavirus infectious disease (COVID-19) and the underlying condition. Early reports demonstrated that patients with cancer had significantly higher risks of poor outcomes of COVID-19, including higher mortality rates, compared to the general population infected...
Source: Clinical Lymphoma, Myeloma and Leukemia - April 13, 2023 Category: Hematology Authors: Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Source Type: research
Autologous stem cell transplant in lymphoma using a noncryopreserved platform: an adapted sequential conditioning maintaining dose intensity does not affect transplantation outcomes.
In this study, we show our experience. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 10, 2023 Category: Hematology Authors: Sarmiento M, Rojas P, Gutierrez C, Quezada J, Jara V, Campbell J, Garcia MJ, Sandoval V, Vergara M, Triantafilo N, Ocqueteau M Source Type: research
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse
The purpose of this investigator-initiated phase II trial was to assess the efficacy of Elo-KRd quadruplet therapy in patients with MM in first relapse. Although the accrual target was not met, our results suggest efficacy and tolerability of this combination in lenalidomide-refractory population enriched for high-risk. Longitudinal immunophenotyping revealed a T cell signature correlating with response. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 6, 2023 Category: Hematology Authors: Manisha Bhutani, David M. Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry Paul, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, Katherine Rigby, James T. Symanowski, Sarah Norek, Mallory R. Tucker, Lawrence J. Druhan, Peter M. V Tags: Original Study Source Type: research
A clinical and correlative study of elotuzumab, carfilzomib, lenalidomide and dexamethasone (Elo-KRd) for lenalidomide refractory multiple myeloma in first relapse
Treatment of patients with multiple myeloma (MM) in first relapse remains a challenge. This phase II study combined elotuzumab (Elo) with carfilzomib, lenalidomide and dexamethasone (KRd) for treatment of MM in first relapse with the aim of improving efficacy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - April 6, 2023 Category: Hematology Authors: Manisha Bhutani, David M Foureau, Myra Robinson, Fei Guo, Kateryna Fesenkova, Shebli Atrash, Barry Paul, Cindy Varga, Reed Friend, Mauricio Pineda-Roman, Katherine Rigby, James T. Symanowski, Sarah Norek, Mallory R Tucker, Lawrence J Druhan, Peter M. Voor Source Type: research
Listening to what matters most: Consumer endorsed patient reported outcome measures (PROMs) for use in multiple myeloma clinical trials: a descriptive exploratory study
This study aimed to identify consumer-endorsed patient reported outcome measures (PROMs) for use in clinical trials with Multiple Myeloma patients. Twenty-six individuals reviewed 10 commonly used PROMs for acceptability, appropriateness, and practicability. The MyPOS, the Brief Fatigue Inventory, and COST-FACIT were endorsed and are proposed for use in future trials where quality of life is an outcome of interest. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2023 Category: Hematology Authors: Hayley Beer, Holly Chung, Simon J Harrison, Hang Quach, Meinir Krishnasamy Source Type: research
The Goldilocks Dilemma in AML: Too Young and Fit, but Not Young and Fit Enough
Acute myeloid leukemia (AML) is principally a disease of older patients, with a median age at diagnosis of 68 years1. In 2020, the landmark VIALE-A trial led to full FDA approval of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly diagnosed AML patients age 75 or older, or patients younger than 75 with one of several qualifying co-morbidities2. In relatively short order, a new standard-of-care was implemented across the world for the majority of AML patients over the age of 75. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 31, 2023 Category: Hematology Authors: Emma C. St. Martin, Tian Yi Zhang, Gabriel N. Mannis Tags: Editorial Source Type: research
SOHO State of the Art Updates and Next Questions |Treatment Approaches for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare variant of Hodgkin lymphoma characterized by a persistent risk of relapse but an excellent overall survival. Historically, it was treated similarly to classic Hodgkin lymphoma, but efforts have been made to deintensify treatment due to risk of late toxicity associated with intensive therapy. For patients with completely resected stage IA NLPHL, no further treatment may be considered, particularly for pediatric patients. For those with stage I-II NLPHL without risk factors such as B symptoms, sites>2, or variant pattern histology, lower intensity treatment wi...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2023 Category: Hematology Authors: Michael S. Binkley, Ranjana H. Advani Tags: Review Article Source Type: research
Treatment approaches for nodular lymphocyte-predominant Hodgkin lymphoma
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare variant of Hodgkin lymphoma characterized by a persistent risk of relapse but an excellent overall survival. Historically, it was treated similarly to classic Hodgkin lymphoma, but efforts have been made to de-intensify treatment due to risk of late toxicity associated with intensive therapy. For patients with completely resected stage IA NLPHL, no further treatment may be considered, particularly for pediatric patients. For those with stage I-II NLPHL without risk factors such as B symptoms, sites>2, or variant pattern histology, lower intensity treatment w...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2023 Category: Hematology Authors: Michael S. Binkley, Ranjana H. Advani Tags: Review Article Source Type: research
FDA analysis of ineligibility for acute myeloid leukemia clinical trials by race and ethnicity
The objective of this study was to analyze the rates and reasons for trial ineligibility by race and ethnicity in trials of acute myeloid leukemia (AML) submitted to the U.S. Food and Drug Administration (FDA) between 2016-2019. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 29, 2023 Category: Hematology Authors: Dianne Pulte, Laura Fernandes, Guo Wei, Ashley Woods, Kelly J. Norsworthy, Nicole Gormley, Bindu Kanapuru, Thomas E. Gwise, Richard Pazdur, Julie Schneider, Marc R. Theoret, Lola A. Fashoyin-Aje, R. Angelo de Claro Tags: Original Study Source Type: research
Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States
: In newly diagnosed stage III/IV classic Hodgkin lymphoma (cHL), A+AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) improved overall survival (OS) versus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). As clinical trial and real-world populations may differ, real-world treatment characteristics and OS (rwOS) were assessed for patients with stage III/IV cHL treated with frontline ABVD. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 29, 2023 Category: Hematology Authors: Allison Winter, Nicholas Liu, Andy Surinach, Michelle Fanale, Kristina S. Yu, Mayur Narkhede Tags: Original Study Source Type: research
